PSMA PET SUVmax Adds Information Beyond Conventional Risk Indices in Localized Prostate Cancer: A Prospective Lesion-Level Radiopathologic Study
- 1David Geffen School of Medicine at UCLA, Los Angeles, CA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA
Abstract
BackgroundProstate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly used to characterize newly diagnosed prostate cancer on the assumption that uptake highlights aggressive disease. However, maximum standardized uptake value (SUVmax) varies widely across localized tumors. Recent genomic assessments have suggested SUVmax reflects tumor biology even when accounting for other tumor indices. Here, we examined highly annotated pathologic, imaging and clinical correlates of intraprostatic SUVmax at the level of individual tumor foci in a prospective multimodal cohort.
MethodsExploratory lesion-level analysis of the radical prostatectomy arm of a single-center prospective diagnostic-accuracy trial (NCT04461509). Patients underwent simultaneous 18F-DCFPyL PSMA PET, multiparametric magnetic resonance imaging (MRI) and high-resolution MRI before prostatectomy, with central blinded pathology and imaging review. Grade Group (GG) [≥]2 foci measuring [≥]10 mm were eligible. The primary outcome was focus-level SUVmax. Correlates spanning histology, tumor microenvironment, MRI and clinical indices were examined by Spearman correlation and rank-based group comparison, followed by separate linear regressions of log(1+SUVmax) each adjusted for GG and tumor size. A digital-pathology sensitivity analysis quantified immune, stromal and tumor pixel-area fractions on hematoxylin and eosin (H&E) sections from a subset of foci using a trained QuPath classifier.
ResultsTwenty-seven patients contributed 34 tumor foci, of which 21 (61.8%) were GG2. Median SUVmax was 5.7 (interquartile range [IQR] 3.9-12.1; range 0.0-57.9). SUVmax rose across the cribriform/intraductal carcinoma (Crib/IDC) gradient (median 3.9, 4.8 and 10.2 for absent, focal and extensive; p = 0.010), correlated with % Gleason pattern 4 ({rho} = +0.47, p = 0.005) and correlated inversely with stromal content ({rho} = -0.40, p = 0.020). Grade Group (p = 0.115), Prostate Imaging Reporting and Data System (PI-RADS) 4 versus 5 (p = 0.705), standard apparent diffusion coefficient (ADC) ({rho} = -0.27, p = 0.130), baseline prostate-specific antigen (PSA) ({rho} = +0.04, p = 0.816) and PSA density ({rho} = -0.02, p = 0.918) were not associated with SUVmax. In separate models of log(1+SUVmax) adjusted for Grade Group and tumor size, % Gleason pattern 4 remained associated with uptake (standardized {beta} = +0.76, 95% CI +0.11 to +1.41), Crib/IDC ({beta} = +0.36, -0.03 to +0.74), and stromal content ({beta} = -0.30, -0.62 to +0.02). On 18 slides re-quantified by pixel classifier, no pixel-based compartment fraction correlated with SUVmax (immune {rho} = -0.06, stroma {rho} = +0.02, tumor {rho} = -0.04; all p > 0.5).
ConclusionsIn this prospective lesion-level cohort, intraprostatic PSMA SUVmax was associated with increased Gleason pattern 4 and cribriform/intraductal burden but not with other common risk indices. SUVmax therefore appears to carry information additive to conventional risk factors. Further investigations examining the tumor biology that reflects SUVmax are warranted.
Related
- Perioperative apalutamide in high-risk localized or locally advanced prostate cancer: Is PROTEUS trial practice changing?
- Feasibility and early outcomes of salvage robot-assisted radical prostatectomy after focal therapy failure for localized prostate cancer
- Exercise During Active Surveillance for Localized Low-Risk Prostate Cancer: Current Evidence and a Survivorship Framework.
- From Radical Treatment to Structured Active Surveillance: A Narrative Review of Low-Risk Localized Prostate Cancer
- Salvage High-Dose-Rate Brachytherapy for Localized Prostate Cancer Recurrence: A Comparative Analysis of 2 Fractionation Schedules-Single-Institution Study of 223 Patients.
BibTeX
@misc{simo2026psma,
title = {{PSMA PET SUVmax Adds Information Beyond Conventional Risk Indices in Localized Prostate Cancer: A Prospective Lesion-Level Radiopathologic Study}},
author = {G. Motchoffo Simo and P. Movva and J. Seo and B. Shou and D. Vega and T. Hagens and E. C. Norris and D. J. Luthringer and A. D'Agnolo and K. H. Sung and J. Calais and W. G. Brisbane and R. E. Reiter and T. J. Daskivich and D. Li and R. Saouaf and H. L. Kim and A. B. Weiner},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.04.26362267},
url = {https://www.medrxiv.org/content/10.64898/2026.09.04.26362267v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - PSMA PET SUVmax Adds Information Beyond Conventional Risk Indices in Localized Prostate Cancer: A Prospective Lesion-Level Radiopathologic Study
AU - G. Motchoffo Simo
AU - P. Movva
AU - J. Seo
AU - B. Shou
AU - D. Vega
AU - T. Hagens
AU - E. C. Norris
AU - D. J. Luthringer
AU - A. D'Agnolo
AU - K. H. Sung
AU - J. Calais
AU - W. G. Brisbane
AU - R. E. Reiter
AU - T. J. Daskivich
AU - D. Li
AU - R. Saouaf
AU - H. L. Kim
AU - A. B. Weiner
PY - 2026
DA - 2026/09/04
PB - medRxiv
DO - 10.64898/2026.09.04.26362267
UR - https://www.medrxiv.org/content/10.64898/2026.09.04.26362267v1
AB - BackgroundProstate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly used to characterize newly diagnosed prostate cancer on the assumption that uptake highlights aggressive disease. However, maximum standardized uptake value (SUVmax) varies widely across localized tumors. Recent genomic assessments have suggested SUVmax reflects tumor biology even when accounting for other tumor indices. Here, we examined highly annotated pathologic, imaging and clinical correlates of intraprostatic SUVmax at the level of individual tumor foci in a prospective multimodal cohort. MethodsExploratory lesion-level analysis of the radical prostatectomy arm of a single-center prospective diagnostic-accuracy trial (NCT04461509). Patients underwent simultaneous 18F-DCFPyL PSMA PET, multiparametric magnetic resonance imaging (MRI) and high-resolution MRI before prostatectomy, with central blinded pathology and imaging review. Grade Group (GG) [≥]2 foci measuring [≥]10 mm were eligible. The primary outcome was focus-level SUVmax. Correlates spanning histology, tumor microenvironment, MRI and clinical indices were examined by Spearman correlation and rank-based group comparison, followed by separate linear regressions of log(1+SUVmax) each adjusted for GG and tumor size. A digital-pathology sensitivity analysis quantified immune, stromal and tumor pixel-area fractions on hematoxylin and eosin (H&E) sections from a subset of foci using a trained QuPath classifier. ResultsTwenty-seven patients contributed 34 tumor foci, of which 21 (61.8%) were GG2. Median SUVmax was 5.7 (interquartile range [IQR] 3.9-12.1; range 0.0-57.9). SUVmax rose across the cribriform/intraductal carcinoma (Crib/IDC) gradient (median 3.9, 4.8 and 10.2 for absent, focal and extensive; p = 0.010), correlated with % Gleason pattern 4 ({rho} = +0.47, p = 0.005) and correlated inversely with stromal content ({rho} = -0.40, p = 0.020). Grade Group (p = 0.115), Prostate Imaging Reporting and Data System (PI-RADS) 4 versus 5 (p = 0.705), standard apparent diffusion coefficient (ADC) ({rho} = -0.27, p = 0.130), baseline prostate-specific antigen (PSA) ({rho} = +0.04, p = 0.816) and PSA density ({rho} = -0.02, p = 0.918) were not associated with SUVmax. In separate models of log(1+SUVmax) adjusted for Grade Group and tumor size, % Gleason pattern 4 remained associated with uptake (standardized {beta} = +0.76, 95% CI +0.11 to +1.41), Crib/IDC ({beta} = +0.36, -0.03 to +0.74), and stromal content ({beta} = -0.30, -0.62 to +0.02). On 18 slides re-quantified by pixel classifier, no pixel-based compartment fraction correlated with SUVmax (immune {rho} = -0.06, stroma {rho} = +0.02, tumor {rho} = -0.04; all p > 0.5). ConclusionsIn this prospective lesion-level cohort, intraprostatic PSMA SUVmax was associated with increased Gleason pattern 4 and cribriform/intraductal burden but not with other common risk indices. SUVmax therefore appears to carry information additive to conventional risk factors. Further investigations examining the tumor biology that reflects SUVmax are warranted.
ER -